In murine models of pulmonary fibrosis, suppression of Nox4 by siRNA or pharmacologic targeting of endogenous Nox by Diphenylene iodonium (DPI) (a well-validated pan-Nox inhibitor) or GKT137831 (putative dual Nox4/Nox1 small-molecule inhibitor) mitigate the development of fibrosis [17,107]. The gene discussed is NOX4; the disease is pulmonary fibrosis.